Khadka et al., 2022 - Google Patents
PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formationKhadka et al., 2022
View HTML- Document ID
- 3842165301817804219
- Author
- Khadka P
- Reitman Z
- Lu S
- Buchan G
- Gionet G
- Dubois F
- Carvalho D
- Shih J
- Zhang S
- Greenwald N
- Zack T
- Shapira O
- Pelton K
- Hartley R
- Bear H
- Georgis Y
- Jarmale S
- Melanson R
- Bonanno K
- Schoolcraft K
- Miller P
- Condurat A
- Gonzalez E
- Qian K
- Morin E
- Langhnoja J
- Lupien L
- Rendo V
- Digiacomo J
- Wang D
- Zhou K
- Kumbhani R
- Guerra Garcia M
- Sinai C
- Becker S
- Schneider R
- Vogelzang J
- Krug K
- Goodale A
- Abid T
- Kalani Z
- Piccioni F
- Beroukhim R
- Persky N
- Root D
- Carcaboso A
- Ebert B
- Fuller C
- Babur O
- Kieran M
- Jones C
- Keshishian H
- Ligon K
- Carr S
- Phoenix T
- Bandopadhayay P
- Publication year
- Publication venue
- Nature communications
External Links
Snippet
The role of PPM1D mutations in de novo gliomagenesis has not been systematically explored. Here we analyze whole genome sequences of 170 pediatric high-grade gliomas and find that truncating mutations in PPM1D that increase the stability of its phosphatase are …
- 230000035772 mutation 0 title abstract description 68
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Khadka et al. | PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation | |
| Liao et al. | Lysine 2-hydroxyisobutyrylation of NAT10 promotes cancer metastasis in an ac4C-dependent manner | |
| Huang et al. | Cancer-cell-derived GABA promotes β-catenin-mediated tumour growth and immunosuppression | |
| Simoneschi et al. | CRL4AMBRA1 is a master regulator of D-type cyclins | |
| Jachimowicz et al. | UBQLN4 represses homologous recombination and is overexpressed in aggressive tumors | |
| Durbin et al. | EP300 selectively controls the enhancer landscape of MYCN-amplified neuroblastoma | |
| Joshi et al. | The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance | |
| Her et al. | Potent effect of the MDM2 inhibitor AMG232 on suppression of glioblastoma stem cells | |
| Liu et al. | A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity | |
| Cervia et al. | A ubiquitination cascade regulating the integrated stress response and survival in carcinomas | |
| Peng et al. | Genome-wide transcriptome profiling of homologous recombination DNA repair | |
| Zeng et al. | LACTB, a novel epigenetic silenced tumor suppressor, inhibits colorectal cancer progression by attenuating MDM2-mediated p53 ubiquitination and degradation | |
| Tonzi et al. | Translesion polymerase kappa-dependent DNA synthesis underlies replication fork recovery | |
| Zhao et al. | A self-amplifying USP14-TAZ loop drives the progression and liver metastasis of pancreatic ductal adenocarcinoma | |
| Moretton et al. | A metabolic map of the DNA damage response identifies PRDX1 in the control of nuclear ROS scavenging and aspartate availability | |
| Tang et al. | Multiplexed screens identify RAS paralogues HRAS and NRAS as suppressors of KRAS-driven lung cancer growth | |
| Li et al. | The deubiquitinase USP7 promotes HNSCC progression via deubiquitinating and stabilizing TAZ | |
| Floren et al. | Tetraspanin CD82 drives acute myeloid leukemia chemoresistance by modulating protein kinase C alpha and β1 integrin activation | |
| So et al. | VRK1 as a synthetic lethal target in VRK2 promoter–methylated cancers of the nervous system | |
| Díaz-Díaz et al. | Proteomic analysis of the E3 ubiquitin-ligase Hakai highlights a role in plasticity of the cytoskeleton dynamics and in the proteasome system | |
| Jiang et al. | Cystatin B increases autophagic flux by sustaining proteolytic activity of cathepsin B and fuels glycolysis in pancreatic cancer: CSTB orchestrates autophagy and glycolysis in PDAC | |
| Carpanese et al. | Interactomic exploration of LRRC8A in volume-regulated anion channels | |
| Li et al. | Comprehensive analysis of PSMD family members and validation of PSMD9 as a potential therapeutic target in human glioblastoma | |
| Wang et al. | Mitochondrial dynamics as a novel treatment strategy for triple‐negative breast cancer | |
| Liu et al. | PTEN loss confers sensitivity to rapalogs in clear cell renal cell carcinoma |